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ON IDENTIFYING POLYCYSTIC OVARY SYNDROME
IN THE CLINICAL DATA WAREHOUSE
AT BOSTON MEDICAL CENTER
JAY JOJO CHENG
ABSTRACT
Introduction
Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenemia, oligo-
anovulation, and numerous ovarian cysts. Although the most common cause of fe-
male factor infertility, its characteristics and metabolic risks are difficult to study
due to its heterogeneity. Additionally, ethnic-specific data is scarce. Hospital
electronic medical records and the diverse patient population at Boston Medical
Center (BMC) may provide an avenue for investigating the longitudinal nature of
PCOS and its race-specific characteristics.
Objectives
1. Describe the Clinical Data Warehouse (CDW) dataset available for studying
PCOS.
2. Develop an automated method for extracting ovarian features from written
ultrasound reports.
3. Identify PCOS patients from their record of the three cardinal PCOS fea-
tures.
v
Methods
Patients evaluated on at least one of the three cardinal PCOS features, between
October 1, 2003 and September 30, 2015 were queried from the BMC CDW. This
thesis describes methods for cleaning the data, as well as the development of an
ultrasound classifier based on natural language processing techniques.
Results
On a validation set of 1000 random ultrasounds, the automatic ultrasound clas-
sifier had a recall and precision for the presence of PCOM, 99.0% and 94.2%, re-
spectively. Overall, 2421 cases of PCOS were identified, with 1010 not receiving a
diagnosis. Black patients had twice the odds of being underdiagnosed compared
to White patients (OR: 2.09; 95% CI: 1.69–2.59).
Conclusions
Ascertaining PCOS through the medical record offers advantages over self-
reported PCOS, including documentation of disease and recorded measurements.
In the future, this PCOS dataset can be used in conjunction with cardiovascular
and metabolic outcomes for developing a predictive model.
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1Chapter 1
Introduction
Polycystic ovary syndrome (PCOS) is a heterogeneous metabolic and reproductive
disorder that affects between 5% and 15% of reproductive-aged women [15]. It is
characterized by hyperandrogenism, oligo-anovulation, and enlarged, polycystic
ovaries. Women who suffer from PCOS are at an increased risk of insulin resis-
tance, obesity, dysfunctional uterine bleeding, and cardiovascular disease [126].
PCOS is currently a leading cause of female factor infertility, yet the difficulty in
its diagnosis and maintenance of long-term follow up for its longitudinal health
risks make it challenging to study [101]. As a result, the disease etiology is un-
known, although some investigators have proposed that the primary defect is in-
creased androgen production in ovarian theca cells [12, 111, 112].
The syndrome is difficult to study in part because the it requires diagnosis
through blood tests, ultrasound tests, and high quality menstrual data. Addi-
tionally, it is a disease of exclusion, meaning that other endocrinopathies must
be ruled out of consideration first before a diagnosis can be made [15, 126]. Fur-
ther complicating its study, retrospective identification seems to be of limited use:
Clark et al. found in 2016 that specificity of self-reported concern for PCOS fea-
tures was rather low; among 126 women who believed they had outward features
of PCOS, only 53% of the women met the NIH criteria, 70% met the Rotterdam
criteria, and 62% met the AE-PCOS criteria [31]. Blood and laboratory tests re-
quire a large commitment from participants, and self-reported (retrospectively
2obtained) menstrual cycle data is often inaccurate [134]. As a result, previous
prevalence studies, which often recruit subjects from infertility clinics, are based
on subgroups not necessarily representative of the general population [104].
Little is known about race-specific PCOS characteristics, since most previous
studies of metabolic syndrome (MBS) in PCOS have study populations composed
of over 90% white women. As a result, race- and ethnic-specific cutoffs for the
diagnostic criteria have not yet been proposed. Furthermore, medically under-
served women and those of low socioeconomic status may not have access to the
resources for treating PCOS, since the disease traditionally falls under the domain
of a reproductive endocrinologist/infertility specialist, whose services the women
may not be able to afford [1, 70, 95, 106, 141]. The diverse patient population ser-
viced by Boston Medical Center (BMC) may provide insight into the race-specific
characteristics of the disease.
On the other hand, hospital-based electronic medical records (EMRs) pro-
vide an avenue for investigating the longitudinal nature of PCOS [75]. Due to
their inherent origin in natural clinical process, the cost of collecting the data is
lower than large-scale epidemiological studies. The trade-off is that they are a
convenience sample1, and care must be taken in generalizing results to the gen-
eral population. Still, depending on how the data is queried from the database,
they may be representative of the clinical population at that hospital and may
offer insights into clinical practice at that location.
This thesis project concerns the mining of the BMC Clinical Data Warehouse
(CDW) for insights into PCOS. It is situated within a larger research program of
1Convenience sampling is a form of non-probability sampling based on data that is readily
obtainable. Because it is nonrandom, a particular process (usually not fully understood) accounts
for how the observations are generated.
3developing a robust model of PCOS phenotype prediction and characterization of
metabolic disease risk.
In particular, this project aims to accomplish the following objectives:
1. Demonstrate how a large dataset generated by natural clinical encounters
can be mined for useful epidemiological insights.
2. Develop a set of tools for preprocessing ultrasound notes and automatic clas-
sification of polycystic ovary morphology (PCOM).
3. Document the characteristics underdiagnosed PCOS patients.
1.1 Brief PCOS history
PCOS was first published on by Irving Stein and Michael Leventhal in 1935 from
observations in seven women complaining about long periods of amenorrhea,
sterility, and hirsutism. The two physicians consistently found enlarged ovaries
in these patients. Upon bilateral wedge resection of the ovaries, they also found
numerous small cysts in the ovarian cortex as well as an absence of corpora lutea
[137]. Since then, the literature on PCOS has grown, with the terms ”polycystic
ovary” and ”Stein and Leventhal Syndrome” appearing in over 38,000 publica-
tions [14].
1.2 Diagnostic criteria
As is the case with other diseases, the definition of PCOS has been refined over
time. Since the beginning, it has always been a disease of exclusion [58]. Clini-
cal diagnosis of PCOS relies on excluding pregnancy and other endocrinopathies
which may cause amenorrhea or androgen excess, including nonclassical adrenal
4hyperplasia, Cushings syndrome, androgen-producing tumors, drug-induced an-
drogen excess, thyroid disorders, and hyperprolactinemia [12].
Between 1990 and 2005, the three modern diagnostic criteria most widely
used today were developed: the 1990 NIH criteria, the 2003 Rotterdam criteria,
and the 2006 Androgen Excess and PCOS Society (AE-PCOS) criteria. In 1990,
a group of investigators attending a National Institutes of Health (NIH) confer-
ence defined PCOS on the basis of a consensus questionnaire to be the combined
presence of hyperandrogenism with oligo-anovulation, and exclusion of other en-
docrinopathies that cause anovulatory infertility.
Before proceeding, it is important here to draw a clear distinction between
the terms “polycystic ovarian morphology” (PCOM) and “polycystic ovary syn-
drome (PCOS).” Polycystic ovary morphology (PCOM) is the abnormal appear-
ance of the ovaries under ultrasound imaging. This abnormality is characterized
by enlarged ovarian stroma and numerous follicles often oriented peripherally.
On the other hand, polycystic ovary syndrome (PCOS) is the heterogeneous dis-
order as a whole. Although PCOM was noticed by Stein and Leventhal in their
original study, there is not necessarily a one-to-one correspondence between the
two; PCOM may not be specific to the disease and not all PCOS women have
PCOM [137]. In fact, under the 1990 NIH criteria, polycystic ovary morphology
under ultrasound was merely considered to be suggestive of PCOS, not necessar-
ily diagnostic, and a woman unaffected by PCOS could have the appearance of
normal ovaries under ultrasound.
In 2003, the Rotterdam consensus criteria expanded the diagnostic criteria
to be at least 2 of the following:
1. clinical or biochemical hyperandrogenism
2. oligo-anovulation
53. polycystic ovary morphology PCOM,
with exclusion of other endocrinopathies [126]. The key change from the 1990
NIH criteria is that hyperandrogenism and oligo-anovulation are no longer both
required for a diagnosis, as long as the patient also has PCOM (Table 1.1). Thus,
the Rotterdam criteria add 2 new phenotypes: the ovulatory phenotype with hy-
perandrogenism and PCOM but no oligo-anovulation, and the normoandrogenic
phenotype with oligo-anovulation and PCOM but no hyperandrogenism.
In recent years, the symptoms which constitute the syndrome have been con-
tested. Most of the controversy surrounds the question of whether or not the
appearance of polycystic ovaries are required and whether or not its presence can
replace either hyperandrogenism of oligo-anovulation. Criticism of the Rotter-
dam criteria mostly focuses on its expansion of phenotypic variability of PCOS
and that some authors feel that PCOM is not a specific enough for PCOS [13, 120].
In their view, extending the criteria results in a uniformity of treatment between
groups women whose metabolic risk may warrant differential approaches.
Some preliminary evidence shows that women with the ovulatory PCOS phe-
notype are less insulin resistant than anovulatory PCOS women [3, 24, 122] and
the normoandrogenic PCOS phenotype are not insulin resistant [20]. The classi-
cal forms of PCOS (those acceptable under the NIH critera) are found to be at the
highest risk of metabolic disturbances [9, 130]. Still, the criteria have also been de-
scribed as better representing the spectrum of the syndrome and the phenotypic
variability [20, 53].
In light of this evidence, the Androgen Excess and PCOS Society convened in
2006 and developed a new set of diagnostic criteria. This new definition pushed
for contracting the previous Rotterdam criteria so that hyperandrogenism was
considered a necessary component. As a result, the normoandrogenic phenotype
6Table 1.1. Comparison of PCOS phenotypes accepted under different
diagnostic criteria
Diagnostic criteria Frank PCOS Non-PCO PCOS Ovulatory PCOS Normoandrogenic PCOS
Hyperandrogenism (HA) + + + -
Oligo-anovulation (IM) + + - +
Polycystic ovary morphology (PCOM) + - + +
Included in 1990 NIH criteria Yes Yes No No
Included in 2003 Rotterdam criteria Yes Yes Yes Yes
Included in 2006 AE-PCOS criteria Yes Yes Yes No
Note. — A similar comparison chart was first published in [13]
no longer appears in this new definition. Still, the Rotterdam criteria are the most
commonly used and because they are inclusive of the other criteria, they will serve
as the baseline criteria used in this study.
1.3 Treatment for PCOS
Over time, treatment for PCOS has evolved. In the early stages of its discovery,
treatment for PCOS was primarily surgical and there was a resistance to using
endocrine therapy [136]. Modern treatment regimens involve various treatments
for the different characteristics of PCOS: treatments for weight loss; insulin resis-
tance; acne and hirsutism; and ovulation.
Obesity increases the risk and severity of all downstream metabolic and re-
productive issues in PCOS women. In 2012, a meta-analysis of 30 studies on
obesity in PCOS found that obesity was associated with decreased sex hormone-
binding globulin (SHBG), increased androgens, hirsutism, fasting glucose, fasting
insulin, and a worse lipid profile [98]. Furthermore, the most effective form of
treatment for endocrine and reproductive function seems to be permanent weight
loss: Kiddy et al. found that even moderate weight loss from long-term calorie
7restriction shows a return of the ability to conceive in most women [84]. Thus,
dietary intervention and weight management is usually a clinical goal; however,
at this time, there are no particular programs that are clearly superior. A meta-
analysis of 10 lifestyle intervention programs in overweight and obese infertile
women found that the median dropout rate was 24% [110]. For patients in whom
dietary intervention is unsuccessful, bariatric surgery represents another option
[26]. Lastly, metformin is used as an insulin sensitizer and it is also associated
with moderate weight reduction [67, 88, 142, 159].
For managing the symptoms of hirsutism, treatments such as electrolysis,
plucking, shaving, waxing, and laser hair removal may be effective in the short
term [39, 131, 149]. Pharmacologic treatments for acne and hirsutism aim to
lower serum androgen levels by lowering androgen production, altering the bind-
ing to plasma proteins, and blocking androgen action [44]. Combined oral con-
traceptives are often used to suppress androgen production and enhance to pro-
duction of SHBG [118, 167]. Antiandrogen treatments such as spironolactone (in
large doses) and finasteride are used to inhibit the binding of dihydrotestosterone
(DHT) to 5α-reductase (5α-RA) [83, 133].
Weight loss and improving insulin sensitivity usually improve ovulation and
menstruation, but if fertility does not return after weight loss, clomiphene citrate
or letrozole may be used for ovulation induction [109, 113, 127, 143]. If this treat-
ment fails, the second line of treatment is administration of gonadotropins, such
as human menopausal gonadotropin (hMG) or recombinant follicle-stimulating
hormone (r FSH) [151].
81.4 Metabolic syndrome in PCOS and race/ethnic considerations
The downstream risk of metabolic syndrome is difficult to study in PCOS patients,
mostly because the chronic nature of the disease warrants long-term follow-up,
which may be costly. Indeed, current estimates of MBS prevalence in PCOS vary
widely by study (Table 1.2), even when restricting to a particular diagnostic crite-
ria.
The race- and ethnic-specific risk adds an additional layer of complexity to
consider. Most studies of PCOS have been in White subjects of continental Euro-
pean descent, although there have been some prevalence studies in other groups
as well. These studies are summarized in Table 1.3. In brief, PCOS prevalence
seems to be higher in South Asians and Hispanics than other ethnic groups.
Other authors have also noted ethnic and racial variations in the expression
of PCOS symptoms, including hirsutism, biochemical hyperandrogenism, PCOM,
and insulin resistance, although the number of studies directly comparing ethnic
profiles are limited. Tables 1.4, 1.5, 1.6, 1.7, and 1.8 summarize of PCOS charac-
teristics by ethnicity. The few studies directly comparing different ethnic groups
are flagged by a superscript and corresponding table note.
The key findings from these studies are that compared to White women with
PCOS, South Asian and Middle Eastern women with PCOS may have more se-
vere hirsutism and insulin resistance even at a lower BMI and testosterone level.
Southeast Asians and Hispanics with PCOS have a higher prevalence of abnormal
glucose tolerance and metabolic syndrome than Whites, and Pacific Islanders have
the highest levels of obesity, hirsutism, and testosterone. Black women seem to be
as hirsute as White women, and are more likely to have hypertension, although
the total number in PCOS studies is low.
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Table 1.3. PCOS prevalence in ethnic groups
Ethnic group and location Prevalence and diagnostic criteria Study
White; Lesbos, Greece 6.77% (13 of 192)1 [38]
White; Madrid, Spain 6.5% (10 of 154)1 [10]
White; Oxford, UK 8% (18 of 224)1 [107]
White and Black; southeastern USA
4.7% (6 of 129) in Whites1
3.4% (5 of 148) in Blacks1
[87]
White and Black; Birmingham, AL
4.8% (8/166) in Whites1
8.1% (18/223) in Blacks1
[17]
Mexican-Americans; Los Angeles, CA 13% (20 of 156)1 [59]
White; Adelaide, Australia
8.7% (63 of 728)1
11.9% (87 of 728)2
10.2% (74 of 728)3
[104]
East Asian; Guangzhou, China 2.2% (20 of 915)1 [30]
Southeast Asian; Chiang Mai, Thailand 5.7% (62 of 1095)2 [148]
South Asian; Gampaha, Sri Lanka 6.3%,(183 of 2915)2 [89]
Arab; 4 provinces representative of Iran
7.1% (66 of 929)1
14.6% (136 of 929)2
11.7% (109 of 929)3
[140]
11990 NIH Criteria
22003 Rotterdam Criteria
32006 AE-PCOS Society Criteria
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1.5 Significance of the study
The race- and ethnic-specific diagnostic criteria are important to consider, be-
cause a diagnosis may mean life-long treatment and management of the disease.
Indeed, what is the difference between 9.99 and 10.01? Should disease manage-
ment depend on such numbers? As the authors of the AE-PCOS guidelines have
written,
“Clinically, diagnosing a woman as having PCOS implies an in-
creased risk for infertility, dysfunctional bleeding, endometrial car-
cinoma, obesity, type 2 diabetes mellitus, dyslipidemia, hyperten-
sion, and possibly cardiovascular disease. . . Furthermore, it has im-
portant familial implications, principally, but not exclusively, for
her sisters and daughters. Finally, a diagnosis of PCOS may mandate
life-long treatments, e.g. the use of insulin sensitizers, and may neg-
atively affect her ability to access health care coverage, principally
in capitalistic markets. Consequently, the diagnosis of PCOS should
not be assigned lightly, and diagnostic criteria should be based on
robust data.” [15]
12
Table 1.4. PCOS characteristics in South Asian populations
Ethnic group Study population Findings Reference
South Asian and White
in UK1
47 South Asian, 40
White
Although South Asian PCOS women were
younger and less obese, they were more hirsute,
more prevalent acanthosis nigricans, and had
higher fasting insulin.
[154]
Sri Lankan 469 PCOS, 231 BMI-
matched controls
PCOS women had more central obesity and
higher insulin resistance than non PCOS. More
prevalent acanthosis nigricans compared to other
studies.
[155]
South Indian 40 PCOS, 40 weight-
matched control
PCOS women had higher fasting insulin, lower
insulin sensitivity, and greater intima-media
thickness, a marker for atherosclerosis.
[138]
North Indian 37 PCOS, 21 non
weight-matched con-
trols
Total and subcutaneous fat volumes were linked
to insulin resistance.
[79]
1This study compared different racial groups.
Table 1.5. PCOS characteristics in Southeast Asian populations
Ethnic group Study population Findings Reference
Thai 531 reproductive-aged
women from the general
population
97.8% had mFG scores <3. Their recommended
cut-off value of mFG in Thai women is 3
[28]
Thai 121 PCOS The prevalence of abnormal glucose tolerance
was 42.9%; acanthosis nigricans was an impor-
tant predictor for abnormal glucose tolerance
[27]
Thai 170 PCOS The prevalence of MBS was 35.3% [150]
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Table 1.6. PCOS characteristics in East Asian populations
Ethnic group Study population Findings Reference
South Chinese 102 PCOS, mean BMI of
21.7
22.4% of Chinese women with PCOS have ab-
normal glucose tolerance. The prevalence of im-
paired glucose tolerance was 20.5% and diabetes
was 1.9%.
[29]
South Chinese 719 PCOS After comparing Rotterdam phenotypes,
metabolic syndrome is most prevalent in
the Frank and Non-PCO phenotypes (28.5% and
25.5%)
[164]
South Chinese 883 PCOS, (˜20% with
BMI >25); 717 controls
Total and subcutaneous fat volumes were linked
to family history of type 2 Diabetes.
[166]
South Chinese 273 PCOS, mean BMI
22.2
Hirsutism in 34%, acne in 45%; the prevalence
of hyperandrogenism, obesity and IR were lower
than in women from other races with PCOS
[62]
South Chinese 915 PCOS women, mean
age 30 years
Prevalence of PCOS was 2.2%; low rates of hir-
sutism, FG score low (13); 7.5% were overweight,
1.3% were obese; hyperandrogenism was age and
BMI dependent
[96]
South Chinese 2988 reproductive-aged
women from the general
population
Cluster analysis identifies mFG score of 5 as
cutoff. This was observed in 10%. Incidence
of PCOS symptoms increased among hirsute
women.
[165]
Chinese 10120 reproductive-
aged women from the
general population
95.5% had an mF-G score <5, mF-G scoring >4
can be used to diagnose hirsutism
[97]
Hong Kong Chinese 197 PCOS, mean BMI of
26
Hyperandrogenic phenotypes were more insulin
resistant and had higher fasting insulin levels.
[91]
Taiwan Chinese 47 PCOS, mean BMI 28;
45 controls
Acanthosis nigricans in 31.9% compared to 0%
and abnormal glucose tolerance in 46.8% com-
pared to 6.25%
[99]
Japanese 46 PCOS Prevalence of hirsutism was only 10%. Total
testosterone had a poor area under the ROC
curve.
[73]
Korean 166 PCOS, 277 controls After sorting into Rotterdam phenotypes, there
were very few ovulatory PCOS phenotype com-
pared to other studies (n=4). Hyperandrogenic
phenotypes had the worst insulin resistance and
fasting insulin levels.
[23]
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Table 1.7. PCOS characteristics in New World populations
Ethnic group Study population Findings Reference
Chilean2 and
Argentinian12
206 PCOS Argentinians,
220 PCOS Chilean
After dividing into Rotterdam phenotypes, BMI
(all phenotypes), triglyceride (Frank, Non-PCO),
LDL-C (Frank, Non-PCO, Ovulatory), and preva-
lence of MBS (all phenotypes) were higher in
Chileans compared to Argentinians.
[34]
White, Black, Asian,
Hispanic and Others,
Northern California1
11,035 PCOS Compared with Whites, Blacks and Hispanics
were more likely and Asians less likely to be
obese; Asians and Hispanics were more likely to
have diabetes; and Blacks were more likely and
Hispanics less likely to have hypertension.
[100]
White and Black,
Alabama1
283 White 350 and
Black, both unselected
to represent the general
population
The 95%ile for mFG was 7.7. With an mFG cut-
off of 8, 5.4% (15) White and 4.3% (15) Black
were considered hirsute. Overall, prevalence and
scores were similar.
[35]
Mexican American, Cal-
ifornia
20 PCOS and 136 con-
trols determined from
screening subjects in a
cardiovascular study
Prevalence (13%) of PCOS in Mexican American
women.
[59]
Mexican American and
White, Texas1
37 Mexican American
PCOS and 65 White
PCOS3
Mexican Americans had higher IR and BMI; in-
sulin resistance was 73% in Mexican American
PCOS women versus 44% in White PCOS women
[82]
Mexican American and
White, Texas1
50 Mexican American
PCOS and 111 White
PCOS3
Mexican American women had higher IR than
white women but lower DHEAS; similar testos-
terone levels between groups
[81]
White, African-
Americans and Asian,
Pennsylvania1
435 White, 109 Black,
17 Asian, 72 Native
American, average BMI
of 35.2
Compared to Whites, fasting insulin was slightly
higher in Blacks and lower in Whites. PCOM
was present in over 90% of the subjects. Asians
tended to have testosterone lower than Whites
and African-Americans
[94]
Note. — New World = Western Hemisphere; Americas
1This study compared different racial groups.
2The ethnic subdivision of the Argentinian population is 87% of European, predominantly Italian, descent; 10%
Hispanic-Amerindian mixture; and 3% other ethnicities while the Chilean PCOS population used is 90% Hispanic-
Amerindian mixture, 7% Amerindian, and 3% other races.
3These two study populations may overlap.
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Table 1.8. PCOS characteristics in European, Middle Eastern, and other
populations
Ethnic group Study population Findings Reference
Muslim Immigrants and
Austrians, Austria1
35 Austrian PCOS, 14
Muslim PCOS
Of the laboratory tests conducted, only SHBG
was markedly different (52.2 nmol/l in Austrians
and 19.0 in Muslim immigrants)
[132]
Turkish 43 PCOS, 43 controls PCOS levels of total testosterone was 94.4ng/dl,
FG score was 13.4, and fasting insulin was
22 µIU/ml. PCOS women had greater carotid
intima-media thickness.
[147]
White and Middle East-
ern, Denmark1
784 White, 190 Mid-
dle Eastern women who
were hirsuite or had
PCOS
Middle East were more hirsute (mean FG 16), but
had lower testosterone levels, BMI, and waist cir-
cumference compared to White women.
[56]
European, Maori, Pacific
Islander1
162 women with at least
one symptom of PCOS
European and Maori women were more hirsute;
Maori and Pacific Island women were more obese
and insulin resistant. Maori women had the
highest testosterone.
[157]
White in Iceland and
Boston; Caucasian,
African-American,
Hispanic, and Asian
women in Boston1
367 PCOS patients, 262
Boston women and 105
Icelandic women
Androstenedione was higher and testosterone
and mFG score were lower in Caucasian Icelandic
compared with Boston women with PCOS; PCO
was demonstrated in 93-100% of women with
PCOS in all ethnic groups
[152]
1This study compared different racial groups.
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Chapter 2
Study Population
2.1 Inclusion and exclusion criteria
The data used in this study was queried from the Boston Medical Center (BMC)
Clinical Data Warehouse (CDW), a repository for historical clinical data. The data
was pulled starting from the date October 1, 2003, when BMC started using its
SDK registration system, until September 30, 2015, the last day BMC used the 9th
version of International Statistical Classification of Diseases and Related Health
Problems (ICD-9). ICD codes are maintained by the World Health Organization
(WHO), and they provide a global standard for coding diseases [6]. After Septem-
ber 30, 2015, BMC switched to the newer ICD-10 codes, but these were not con-
sidered for the present study because of the additional variance they introduce.
The inclusion criteria for this study require that the subjects be female, be of
reproductive age (between 18 and 45), and have records at BMC for at least one of
the following: androgen blood tests, menstrual regularity, and pelvic ultrasound.
In particular, Table 2.1 describes the specific CDW queries for these inclusion
criteria. These inclusion criteria allow us to include both women who are consid-
ered normal and women who considered abnormal on each of the three polycystic
ovary syndrome (PCOS) axes to be included, with the limitation that those who
are administered an androgen lab or a pelvic ultrasound are more likely to have
abnormalities. In essence, this dataset captures all women appearing at BMC
who have the potential to be diagnosed with PCOS. Women who were younger
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Table 2.1. CDW inclusion queries
Inclusion criteria ICD-9 code, lab, or procedure
Evaluation of
androgens
704.1 - hirsutism
Total testosterone lab
Free testosterone lab
Bioavailable testosterone lab
Evaluation of
menstrual regularity
626.0 - absence of menstruation
626.1 - scanty or infrequent
menstruation
626.4 - irregular menstrual cycle
Evaluation of
pelvic ultrasound
Pelvic ultrasound
than 18 at any point in this study and those who were older than 45 at any point
in this study had their data left-censored and right-censored respectively at those
ages. Similarly, those given a specific diagnosis of menopause had their data right-
censored at that time. This resulted in a study population of 37,959 women.
Table 2.2 gives the endocrinopathies for exclusion. This list of ICD-9 codes
was generated by examining all possible ICD-9 codes and retaining the ones that
may cause oligo-amenorrhea, hyperandrogenism, or infertility. Thus, it spans the
set of all endocrinopathies considered by the WHO. Any woman with one of these
ICD codes had her data completely excluded from the study. Overall, there were
1679 women excluded by the presence of a disorder appearing on this list.
2.2 Study population characteristics
Our dataset is the most diverse for PCOS. About 43% of the women are
Black/African-American, 26% are White, 17% are Hispanic/Latino, and 4.4% are
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Table 2.2. CDW exclusion queries
Endocrinopathy ICD-9 code
Malignant neoplasm of corpus uteri, except isthmus 182.0
Goiter, specified as simple 240.0
Goiter, unspecified 240.9
Nontoxic uninodular goiter 241.0
Nontoxic multinodular goiter 241.1
Thyrotoxicosis with or without goiter 242
Congenital hypothyroidism 243
Acquired hypothyroidism 244
Thyroiditis 245
Other disorders of thyroid 246
Cushings syndrome 255.0
Hyperaldosteronism 255.1
Adrenogenital disorders 255.2
Other corticoadrenal overactivity 255.3
Corticoadrenal insufficiency 255.4
Other adrenal hypofunction 255.5
Medulloadrenal hyperfunction 255.6
Other specified disorders of adrenal glands 255.8
Unspecified disorder of adrenal glands 255.9
Other ovarian dysfunction 256.8
Asian. American Indian/Native American, Middle Eastern, and Native Hawai-
ian/Pacific Islander categories accounted for less than 2% of the dataset. About a
quarter did not attend or complete secondary school and another quarter either
finished or received a GED. Almost 15% had some kind of higher education and
under 20% graduated college.
In the future, it would be better to develop more refined race/ethnicity cate-
gories. For example, South Asians and East Asians are all coded as Asian within
this study, but PCOS characteristics may be dependent on the race and ethnicity
to an even finer degree [161]. For example, Wijeyaratne et al. found that hirsutism
was more prevalent and severe among PCOS patients of South Asian ancestry than
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those of European White ancestry [154]. On the other hand, at the same androgen
level, East Asian subjects have lesser degree of hirsutism than White subjects [49].
As a result, grouping South Asians and East Asians together results in information
loss about some race-specific nuances.
Along the same vein, Boston has a significant Cape Verdean and Haitian pop-
ulation, which are usually coded as “African-American” or “Other” within the
CDW dataset, yet these recent immigrant populations have cultural practices and
diets distinct from Black Americans whose families trace their history within the
country for a few generations. Future studies that aim to understand the influence
of lifestyle characteristics and genetics on PCOS should take care to distinguish
between these people groups.
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Table 2.3. Study population characteristics
Characteristic (n = 37959) % (n) or mean ± SD
Age
Age on 2015/9/30 36.7 (8.9) years
Race
American Indian/Native American 0.5638% (214)
Asian 4.415% (1676)
Black/African American 43.49% (16510)
Hispanic/Latino 17.15% (6509)
Middle Eastern 0.9879% (375)
Native Hawaiian/Pacific Islander 0.08957% (34)
Non-Hispanic White 26.03% (9880)
Other/Multiracial 4.418% (1677)
Declined/Not Available 2.856% (1084)
Anthropometrics
Height (cm) (n = 27325) 162.4 ± 7.1
Weight (kg) (n= 31889) 76.2 ± 20.5
BMI (n = 28371)
Underweight <18.5 1.6% (450)
Normal weight 18.5-24.9 32.1% (9115)
Overweight 25-29.9 28.9% (8198)
Obese Class I 30-35 18.8% (5344)
Obese Class II 35-40 10.1% (2855)
Obese Class III >40 8.5% (2409)
Blood pressure (n = 32560)
Systolic blood pressure (mmHg) 118.0 ± 11.6
Diastolic blood pressure (mmHg) 75.1 ± 7.5
Socioeconomic status
Education
Did not attend school 4.536% (1722)
8th grade or less 4.268% (1620)
Some high school 19.84% (7532)
Graduated high school or GED 24.32% (9232)
Some college/vocational school/technical school 14.21% (5394)
Graduated college/postgrad. 19.74% (7496)
Other Education 0.7034% (267)
Declined/Not Available 12.37% (4696)
21
Table 2.3 (cont’d)
Characteristic (n = 37959) % (n) or mean ± SD
Reproductive
Age at Menarche (n = 273) 12.7 ± 2.0
Note. — For repeated measurements, a within-
woman average was calculated first. Then these are
used to calculate the measures of central tendency
and dispersion.
2.3 Characteristics of the Clinical Data Warehouse dataset
Because the dataset was generated by natural clinical processes and was not orig-
inally collected for research purposes, many variables in the data needed to be
cleaned before they were suitable for analysis. For example, before cleaning, many
nonsensical BMI values appeared in the dataset (Figure 2.1).
There are so many large outliers that the interquartile range looks like a line
at this resolution! For comparison, the heaviest recorded weight for an adult man
is 635 kg, and he stood 1.85 meters tall, which puts his BMI at 185.5 [61]. Clearly
BMI values several orders of magnitude greater than that are absurd. The goal
in this part of the analysis was to salvage as much usable data as possible for
the purposes of characterizing the study population and also later development
into a predictive model involving metabolic characteristics. The following sub-
sections describe the preprocessing of the race, anthropometrics, socioeconomic
status (SES), and reproductive data characterizing the population.
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Fig. 2.1 Boxplot of crude BMI data in the CDW dataset
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Table 2.4. The same ratio between true and given BMI values within a cluster
ID BMI Height (m) Weight (kg) New BMI Ratio
4558 78548.42 1.18 70.5 50.6 1552.36
6617 29090.91 1.97 72.7 18.7 1552.36
10151 80068.71 1.18 71.8 51.6 1552.36
16693 38363.64 1.97 95.9 24.7 1552.36
177881 35818.18 1.97 89.5 23.1 1552.36
177881 39841.82 1.97 99.6 25.7 1552.36
Note. — The first BMI column (BMI) contains the given values and
the second BMI column (New BMI) contains the recalculated values.
1These entries represent the same patient on different hospital visits.
2.3.1 Anthropometric data
Visual inspection of the boxplot of crude BMI in Figure 2.1 reveals that there seem
to be clusters between 100 and 40,000; 40,000 and 70,000; 70,000 and 100,000;
and over 100,000. Since BMI is computed in practice from clinically measured
weight and height – that is, BMI is not measured directly, but instead calculated
from directly measured values – this suggests that the BMI computations may
be the least trustworthy among height, weight, and BMI values in the dataset.
Within each of these outlying clusters, a similar systematic error may pervade the
measurements and indeed, a preliminary analysis revealed that within a cluster,
when a “true BMI” was calculated from seemingly reliable weight and height data,
the true BMI falls within normal ranges of human experience. Even more striking
is that the ratio between the given “false BMI” and calculated BMI are similar
between data points. Table 2.4 shows a sample calculation for some data points
between 35,000 and 80,000 that fit this description.
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Table 2.5. Examples of mixed units for height in the dataset
Meters Inches Centimeters Feet & inches Ambiguous
1.97 64 166 5.2 17.717
To preserve as much BMI information as possible for analysis, an interme-
diate step of cleaning the height and weight data was necessary, as some obser-
vations did not have a recorded BMI but did have measurements for height and
weight. Of height and weight, the height data was cleaned first and similar to
the BMI data, there were clusters of points along its range. Manual inspection of
the height data revealed that it seemed to be recorded in a variety of measure-
ment units, e.g. “1.97,” “64,” “166,” “5.2,” and “17.717” (Table 2.5). It is clear
that measurements of the first type refers to meters, the second to inches, and
the third to centimeters, but the fourth type is unclear. Does it mean 5 feet and
2 inches or 5.2 feet? As elaborated later, a nuance within measurements in this
category allowed a well-defined ascertainment. Measurements of the fifth type
were completely incomprehensible and were counted as missing. This category
included the extremely large values for which no explanation could be mustered,
e.g. “0.39,” “2007.00,” “26444.00.” Thus, to clean the heights, the data was first
sorted into five categories: “meters,” “inches,” “centimeters,” “feet & inches,” and
“mark as missing.”
Further inspection of the “feet & inches” category revealed some nuances in
how it was recorded. For example, there were entries for 5.10 and 5.11, but never
5.12 (or 5.13, 5.14, etc.). There also seemed to be a difference between 5.10 and
5.1, with the latter group tending to have lower weights. Thus, the height data in
this category was interpreted such that the digits to the right of the decimal place
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referred to the number of inches and the digit to the left referred to the number
of feet.
During this process, some of the heights and weights seemed as if they should
be switched. For example, an observation with a weight entry of 60 and height
entry of 300 probably represent a woman who is 60 inches tall and who weighs
300 pounds, rather than a 25 foot tall woman weighing 60 pounds. As a rule of
thumb and barring extreme observations, it seemed safe to assume that weight
in pounds would always exceed height in inches, so outliers with heights in line
with normal weight ranges (100–300) and weights in normal height ranges (40–
80) were flipped. There were 16 such cases and their median “height” was 137.5
(range 107–372) and median “weight” was 64 (range 50–68). In 11 cases, the
patients other entries in BMI, weight, or height from separate occasions confirmed
that this type of error occurred and that the swap was warranted.
According to the CDCs Anthropometric Reference Data for Children and Adults:
United States, 2007-2010, a 5 standard deviation range in height covers 50 inches
to 77 inches (127–196 cm) [54]. Thus, the final criterion for marking as missing
(fifth category) was the value of height falling in one of the following intervals:
between 7 and 49 (values too small to be inches), between 78 and 126 (values too
large to be inches and too small to be centimeters) or above 197 (values too large
to be centimeters). After exclusion, the data were standardized to inches, which
was the most common measurement, using the conversion ratio of 1 : 0.393701
centimeters to inches. This resulted in 81,101 complete height measurements in
27,325 unique patients.
The weight data exhibited the best general behavior of the three. There was a
scattering of large values above 600 and small values, but otherwise the histogram
between 0 and 600 is rather good (Figures 2.2 & 2.3).
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Fig. 2.2 Boxplot of crude weight data in the CDW dataset
Fig. 2.3 Histogram of crude weight data between values 0 to 600
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The weight data were also presumed to span different units, but here the
same trick used for the height data was not able to be applied because the numeric
value of weight for imperial and metric units overlaps between categories even at
3 standard deviations of human experience: 87–297 pounds and 40–136 kg [54].
Thus, values between 87 and 136 were ambiguous due to this issue. Furthermore,
weights below 40 kg and weights above 297 were credulous, since BMC’s service
population does not preclude those with extremely low or high bodyweight, a
reflection of the large homeless and poor population it serves.
To determine the right unit for each observation, a combination of BMI,
height, and historical data was used. Before that, the values for BMI below the
limit of human female starvation, 11, were removed [66]. Next weights below 17
were removed, since 17 kg would correspond to the weight of the shortest woman
in this data set at a BMI of 11. Weights with entries between 17 and 40 would
be in kilograms presumably, if it all possible, and these were only kept if they
harmonized with a matching BMI and height measurement as well as previous
measurements; those missing either BMI, height, or other records confirming this
measurement were changed to missing. To summarize this step, values that rep-
resent an impossible physical reality were removed and those that corresponded
to starvation were only kept if they were confirmed by all other measurements.
In the final and most time-intensive step, all weights in the dataset were
double-checked for correctness of units by comparing its numeric value with pre-
vious and future hospital visits. Table 2.6 demonstrates an example of this pro-
cess. When a unit conversion was more in line with the patient’s history, the con-
verted version was preferred.
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Table 2.6. Comparison of weight with the patient’s history
ID Clinical date BMI Height Weight SBP DBP
509 8/29/2007 33.42 180 110 90
509 9/17/2007 178 125 80
509 12/13/2007 34.72 187 120 80
509 6/4/2008 37.32 201 100 90
509 5/19/2009 93.91 130 88
509 6/29/2009 39 212 126 90
509 1/13/2010 38.62 208 130 88
509 4/21/2010 39.17 211 114 76
509 5/5/2010 40 61.8 215 147 87
1Instead of believing the patient could gain over 100 lbs in
a month, 93.9 (kg) was converted to 207 (pounds), which is
more in line with the patient’s history.
2.3.2 Reproductive data
The data for age at menarche also needed refining. The main issue was that the
range of values in the dataset did not line up with clinical experience. Some-
times this was because it was not formatted similarly; these entries were usually
recorded as years, e.g. 14 or 14y, and occasionally as dates, which could then
help triangulate the age at menarche in conjunction with the subjects current age.
However, there were others with integers that were much larger, such as 28 and
28d. Interestingly, for many of these cases, the patients had other age at menarche
entries within a reasonable range. Due to the d and the prevalence of 28, these
are considered estimates of the patients cycle length mistakenly entered into this
form. All records with age at menarche greater than 19 were hand-checked, and
those greater than age 22 were determined to be errors due to the presence of d
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Table 2.7. Summary of menarche outliers
Summary measure Value
Min. 23.0
1st Quartile 25.5
Median 28.0
Mean 43.1
3rd Quartile 41.0
Max. 114.0
or being greater than 40. There were 12 such observations. The following table
presents the characteristics of these outliers.
There were likewise many small values that were considered errors. It is less
certain what the mistake was. Here, the mode of these values was 1. All values less
than 8 were handchecked, and those equal to 3 or smaller were considered errors.
There were 6 such observations. A boxplot of the processed data is displayed in
Figure 2.4.
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Fig. 2.4 Boxplot age at menarche data after processing
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Chapter 3
Hyperandrogenism
3.1 Background
3.1.1 Clinical vs biochemical hyperandrogenism
Clinical hyperandrogenism, or hirsutism, is the presence of excess body and ter-
minal hair growth in females in a male-like pattern [161]. It is the most recogniz-
able feature of polycystic ovary syndrome (PCOS) and conversely, it has great sen-
sitivity; Adams et al. found in 1986 that 92% of women with regular menstrual
cycles and hirsutism also presented with polycystic ovary morphology (PCOM)
under ultrasound [2].
When surveyed, hirsute women display a greater measures of social fear and
anxiety [135]. Other quality of life surveys comparing PCOS women to controls
found that PCOS women were less satisfied with their sex life, found themselves
less sexually attractive, and believed their partners were less satisfied [47, 63].
Surveyed women believed to a greater extent that their excessive body hair nega-
tively affected their sexuality and ability to form social contacts.
On the other hand, biochemical hyperandrogenism is defined as elevated
serum androgens. Testosterone is the chief male sex hormone responsible for
development of male sex characteristics and spermatogenesis. In women, it is
produced in the ovaries in a smaller amount, and both sexes produce it in the
adrenal cortex. Around 60% of testosterone is specifically bound to sex hormone-
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binding globulin (SHBG) and another 38% is nonspecifically bound to albumin
[85, 145]. The remaining 2% is in an unbound state, called free testosterone
[41, 125]. The physiologically important levels of testosterone are the nonspecif-
ically bound and free testosterone and as a result, an increase of SHBG decreases
the bioavailability of testosterone, even if the total testosterone levels remain the
same. To be more explicit, if nonspecifically bound testosterone (albumin-bound)
is represented as AT and free testosterone will be represented as FT, the following
relationship holds:
BT = FT + AT, (3.1)
where BT is bioavailable testosterone.
3.1.2 Biological mechanism
Terminal (coarse) hairs are distinct from vellus hairs, which are short, fine, and
non-pigmented. An excess of vellus hairs is not hirsutism, and instead referred to
as hypertrichosis, which may be caused by corticosteroid or prostaglandin admin-
istration [65, 76, 77]. However, some hair follicles can ”terminalize” vellus hairs,
converting them into terminal hairs under the influence of androgens [42, 55].
Virilization in mammals is accomplished by both testosterone and its
metabolite dihydrotestosterone, with the latter being the more potent [128]. The
enzyme responsible for reducing testosterone to dihydrotestosterone (DHT) is 5α-
reductase (5α-RA). The relation to PCOS is that in human and rat scrotal fibrob-
lasts, addition of a monoclonal antibody against insulin-like growth factor 1 (IGF-
1) reduces the effect of dihydrotestosterone [69]. In 2005, Cappel et al. noted that
in women with clinical acne, IGF-1 correlated with DHT, and there was an inter-
action effect between IGF-1 and DHT on acne lesion counts [102]. Other studies
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have noted the elevated IGF-1 levels in hyperandrogenic disorders and idiopathic
hirsutism [4, 48].
3.1.3 Evaluation of clinical hyperandrogenism
The most common1 method of evaluating hirsutism is the modified Ferriman-
Gallwey (mFG) score, a modified version of the method originally described by
David Ferriman and John Gallwey in 1961 [52, 64]. The original version called for
the evaluation of 11 regions of the body: lip, chin, chest, upper back, sacro-iliac
region, upper abdomen, lower abdomen, arm, posterior forearm, thigh, and leg.
Since hair growth on the lower leg and forearm were found to be independent of
the hair on the other 9 regions, the modified version of the does not include them.
In both the original and modified version of the scoring system, each region is
assigned a score of 0-4, with 0 representing the absence of terminal hairs, 1 rep-
resenting minimally evident terminal hair growth, and 4 representing extensive
hair growth comparable to that in males. These scores are then summed and the
aggregate score is then used to determine the presence of absence of hirsutism
[10, 52, 64, 129].
There is still room for improvement on the front of assessing hirsutism: the
metric (of summing the regional scores to find a total) used alongside the popular
mFG system does not match conventional intuition about severity of hirsutism.
As a simple counterexample, one could consider two hypothetical white female
patients: the first patient scoring “1” (minimally evident terminal hair growth)
in each body part would receive a total mFG score of “9,” and a second patient
scoring “3” only in the chin and the upper lip would receive a total mFG score
of “6.” Most mFG cutoffs in white women vacillate between 8 and 9 (Table 3.1),
1The pervasiveness is still largely restricted to research studies, as patients and practitioners
often consider a full body examination too invasive for the added marginal benefit [86].
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Table 3.1. Determinations of mFG cutoffs in unselected White women
Location Study population size mFG cutoff Study
Spain 154 8 [10]
USA 283 8 [35]
and so the first patient would technically be classified as hirsute while the second
would be classified as normal.
The inherent issue is common to any problem regarding comparisons with
multivariate objects (e.g. college rankings) and essentially, the summation over
all body regions results in two difficulties: first, equating the change from “0”
to “1” and “1” to “2” within a region (assuming equal intervals for an ordinal
variable) and second, equating the change from “0” to “1” between two regions
(assuming equal units).
This issue has also come to the attention of other investigators, as well as
the issue of inter-observer variation, which increases with an increasing number
of dimensions (body part regions) to measure [8, 156]. In particular, Cook et al.
proposed in 2011 a simplified scoring system using only the sum of scores from
the upper abdomen, lower abdomen and chin, but their proposal has not gained
widespread acceptance [32].
3.1.4 Evaluation of biochemical hyperandrogenism
Since bioavailable testosterone is the physiologically meaningful quantity, any
measure of hyperandrogenism at least indirectly measures the bioavailable testos-
terone. Based on the law of mass action, the equilibrium equation for albumin
binding to testosterone is AT = Ka · Ca · FT, where AT and FT are the concen-
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trations of albumin-bound testosterone and free testosterone, respectively, Ka is
the association constant of albumin for testosterone and Ca is the concentration
of albumin, so AT is linearly proportional to FT at constant concentrations of
albumin. Thus, several methods measure free testosterone and the concentra-
tion of albumin in order to calculate albumin-bound testosterone and bioavail-
able testosterone. One drawback to these methods is that reliable direct measure-
ment of free testosterone remains elusive, because the procedures available are
time-consuming and the amount of free testosterone is a tiny proportion of total
testosterone [33, 115, 139, 145]. The lack of sensitivity and accuracy of measuring
free testosterone is especially apparent in women, who have naturally lower levels
[124].
Another option is to use the free androgen index (FAI), defined as
FAI = 100
Total testosterone
SHBG
, (3.2)
but opinion in the current literature is mixed. Vermeulen et al. found that FAI
does not correlate well, but other studies have found correlation coefficients rang-
ing between r = 0.86 and r = 0.93 in adult females [80, 108, 145]
Once androgens are quantified, it is necessary to delineate the boundary be-
tween normal and hyperandrogenemia. The diagnostic criteria do not explicitly
give cutoffs for biochemical hyperandrogenism, but in practice, a common cut-
off used is 2 standard deviations above the mean within ovulatory, nonhirsute
women. This value will vary between studies and labs due to variability in mea-
suring testosterone at the levels present in adult women [124].
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3.2 Methods
3.2.1 Evaluation of hyperandrogenism within the study
Within the study, hirsutism was ascertained through the ICD-9 code 704.1. Acne
was briefly considered for the study, since a third of younger PCOS women present
with acne [15]. However, it is a nonspecific finding and there is no information
about its severity within this dataset. Furthermore, due to its pervasiveness in
adolescents and young adults in general, it is that unknown whether someone
without an ICD diagnosis for acne is actually acne free and whether someone
with an ICD diagnosis actually has a clinically severe case.
The cutoff points for biochemical hyperandrogenism was determined by
finding the 95th percentile of free testosterone, bioavailable testosterone, and to-
tal testosterone within the study population, after excluding those with irregular
menstrual cycles, hirsutism, and PCOM (Chapter 4). These empirical cutoffs were
12 pg/mL, 23.3 ng/dL, and 63 ng/dL, respectively.
3.2.2 Limit of detection
Prior to preprocessing, some entries in the free testosterone, total testosterone,
and bioavailable testosterone data below the limit of detection (LOD). These were
usually indicated by an entry that looks like “< LOD.” These nondetects were
assigned the value
LOD√
2
. (3.3)
Since the limit of detection was so far below cutoff points, nondetects did not
affect the classification of those patients. Additionally, using LOD√
2
preserves the
mean in normally distributed data.
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Table 3.2. Summary of testosterone labs
Summary measure Total testosterone Bioavailable testosterone Free testosterone
Min. 0.7 0.1 0.1
1st Quartile 20.0 3.4 1.8
Median 32.0 6.8 3.4
Mean 56.7 13.3 6.5
3rd Quartile 50.0 13.2 6.7
Max. 3784 3201 1408
3.3 Results
904 women had the code for hirsutism and 626 women had androgen levels
above the cutoffs determined previously. Altogether, 1444 unique women had hy-
perandrogenemia. Table 3.2 gives the summary measures for total testosterone,
bioavailable testosterone, and free testosterone.
3.4 Limitations
The total testosterone and bioavauilable testosterone cutoffs were comparable to
those found in other studies, but the free testosterone cutoff measured here was
over 30% greater than other estimates [5, 16, 82, 104]. The large difference is
probably due to a bias toward abnormal values for women who are evaluated at a
hospital. The following quantile-quantile plots comparing the distribution of the
lab values to normality confirm that this is likely the case (Figure 3.1). Therefore,
because the cutoffs are skewed higher, there are likely other women in the dataset
who would be considered hyperandrogenic if cutoffs derived from an unselected
population had been used instead.
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Fig. 3.1 Quantile-quantile plot of testosterone labs. The top left is free testos-
terone, top right is bioavailable testosterone, and bottom left is total testosterone.
The data exhibit right-skewness, heavy-tailedness, and possible bimodality.
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Chapter 4
Oligo-anovulation/oligo-amenorrhea
4.1 Background
Oligo-ovulation is infrequent or irregular ovulation and anovulation is the ab-
sence of ovulation [92]. Most polycystic ovary syndrome (PCOS) patients are di-
agnosed in an infertility clinic, first presenting with oligo- or anovulation [22]. For
most patients, ovulation can be restored, but some studies have demonstrated that
oligoovulatory PCOS women have milder symptoms than anovulatory women,
and that they respond better to ovulation induction treatments and have higher
live birth rates after fertility treatment [22, 71, 72].
4.1.1 Biological mechanism
The etiology of oligo-anovulation in PCOS is not fully understood and nearly 12%
of PCOS patients who present with oligo- or amenorrhea still show signs of spon-
taneous ovulation [22]. As mentioned in the discussion of treatments in Section
1.3, weight loss and insulin sensitization often returns ovulation to PCOS women.
Willis et al. found that granulosa cells from anovulatory PCOS women were more
responsive to luteinizing hormone (LH) than granulosa cells from ovulatory PCOS
women and suggest that insulin acts to sensitize granulosa cells to LH and leads to
premature maturation of these cells [158]. In animal models, Wu et al. found that
mice with diet-induced obesity were infertile and hyperandrogenic, while obese
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mice with a disrupted insulin receptor gene on theca-interstitial cells in the ovary
exhibited improved fertility and testosterone levels similar to lean mice [160].
4.1.2 Evaluation of oligo-anovulation and oligo-amenorrhea
The gold standard for detecting ovulation is ultrasound visualization, but meth-
ods involving the measurement of hormones in blood or urine have also been
validated [7, 18, 116]. Currently, two main hormone markers are used to detect
ovulation [74, 123]. The most common markers used are elevated serum pro-
gesterone and elevated urinary prenanediol 3-glucuronide [62, 90, 109, 114]. In
practice, oligo-anovulation may be substituted by oligo-amenorrhea, defined as
menstrual cycles longer than 35 days, and anovulation is usually diagnosed clini-
cally as amenorrhea, defined as less than 10 menstruations per year [121].
4.2 Methods
4.2.1 Evaluation of oligo-anovulation within the study
Within the study, oligo-anovulation/oligo-amenorrhea was ascertained by the
presence of ICD-9 codes 626.0, absence of menstruation; 626.1, scanty or in-
frequent menstruation; and 626.4, irregular menstrual cycle. One assumption
here is that women who have irregular cycles will report it to their caregiver such
that those without these ICD-9 codes will have fairly regular menstrual cycles.
However, this may not necessarily be the case and it is almost certain that some
women with irregular menstrual cycles were not detected. Some of the diagnoses
appeared after documentation of menopause, so these were censored.
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Table 4.1. Summary of age at diagnosis of irregular menstrual cycles
Summary measure Value
Min. 24.0
1st Quartile 36.6
Median 40.2
Mean 39.6
3rd Quartile 42.9
Max. 45.0
4.3 Results
Using the ICD-9 codes, a total of 7088 premenopausal women were identified as
having irregular menstrual cycles. Table 4.1 summarizes the age at diagnosis.
4.4 Limitations
One limitation of this method is that the women represented by this diagnostic
code may include menopausal women. Even after excluding those given an ICD-
9 code diagnosis, there remained subjects that received the diagnosis at age 45
(Table 4.1). The selection of 45 was arbitrary, and 44 or 43 could have just as
easily been chosen. Thus, a minority of those identified may have had irregular
menses due to an earlier menopause, rather than PCOS.
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Chapter 5
Polycystic ovarian morphology
5.1 Background
The 2003 Rotterdam Consensus criteria that define polycystic ovary morphology
(PCOM) as the “Presence of 12 or more follicles in each ovary measuring 29 mm
in diameter, and/or increased ovarian volume (10 mL),” are based off of Pache
et al., 1992; van Santbrink et al., 1997; and Jonard et al., 2003 [78, 117, 144],
which were the available literature at the time. Since then, there is evidence that
the improved resolution of newer ultrasound technology increases the number
of observable follicles, and thus inflates the number of PCOM that is diagnosed
[36]. For this reason, some authors have proposed changing the cutoff from 12
follicles to 20 or abandoning ultrasound altogether in favor of other biomarkers,
such as serum anti-Mu¨llerian hormone (AMH) [37, 46]. Current open questions
about PCOM include characterizing the variability of ovarian volume measure-
ments and understanding its physiology.
5.2 Methods
5.2.1 Description of the problem
Although the images themselves were not used in this analysis, the great majority
of ultrasounds included 3-dimensional measurements of ovarian size and details
about ovarian morphology, including the counts, echogenicity, and sizes of folli-
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cles and other ovarian abnormalities. This enabled calculation of ovarian volume
to compare with the cutoff of 10 ml given by the Rotterdam Criteria in the absence
of a dominant follicle, “According to the available literature, the criteria fulfilling
sufficient specificity and sensitivity to define PCO are the following: ‘presence
of 12 or more follicles in each ovary measuring 29 mm in diameter, and/or in-
creased ovarian volume (>10 ml)’. The subjective appearance of PCO should not
be substituted for this definition” [126].
Of the three PCOS diagnostic criteria, evaluating for polycystic ovary mor-
phology from radiology notes was the most challenging. Physician notes were
pulled from the Clinical Data Warehouse (CDW) about the indication, find-
ings, and impression for each pelvic ultrasound. There were 39,093 ultrasounds
in the database for 25,535 unique patients and in total, this corpus consisted
of 3,707,837 words, with each observation containing 94.84657 words on aver-
age. As a comparison for understanding the magnitude of this dataset, Herman
Melville’s Moby-Dick is 209,117 words long. Here is what a typical observation
might look like:1
ID: 10469
Clinical date: 5/7/2007
History: 38-year-old female with right lower quadrant cystic lesion identified on
CT scan of April 30; 2007. Patient dictaphone tb with April 16; 2007.
Findings: Transvaginal pelvic ultrasound was performed for optimum visualiza-
tion of the uterus and the adnexa. Transabdominal pelvic ultrasound was per-
formed for evaluation of the remainder of the pelvic contents. Uterus measures
6.7x5.0x5.4 cm. . Endometrial stripe measures 8 mm. Myometrium appears
heterogeneous with areas of shadowing and subtle cystic areas within the my-
1All patient identifiers were stripped before analysis. Shown below is a randomized study ID.
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ometrium. The appearance suggests adenomyosis. No discrete submucosal fi-
broid identified. Right ovary measures 6.5x6.3x5.7 cm. There is a cyst measuring
approximately 6 cm in size located centrally within the right ovary with a thin rim
of peripheral tissue. Cyst is hemorrhagic with low-level internal echoes. No solid
component a mural nodule. The cyst is avascular. Taking into account differences
in imaging technique; the cyst appears to have increased in size compared to the
CT scan. Would recommend followup ultrasound in approximately 2 or 3 men-
strual cycles. If cyst persists; would recommend MRI for further evaluation. Left
ovary measures 2.9x1.7x2.16. Left ovary is normal. No free pelvic fluid. Limited
evaluation of the right and left kidneys demonstrates no obstruction.
Impression: Approximate 6 cm hemorrhagic appearing cyst in the right ovary
which appears to have enlarged compared to a prior CT scan; as described .
Would recommend followup ultrasound in approximate 2 or 3 menstrual cycles.
If cyst persists; would recommend MRI for further evaluation. Evidence for ade-
nomyosis of the uterus. MRI can be used to confirm suspected adenomyosis if
clinically indicated.
From this type of data, it was necessary to extract measurements of each
ovary, assign the measurement to the proper side, “avoid” notes about other or-
gans, and identify important morphological features.
5.2.2 Approach to the problem
The general strategy was to make use of the pervasive ovarian volume measure-
ments and compare them to the threshold provided by the diagnostic criteria.
Since ovarian volume changes along the menstrual cycle, using the volume cut-
off for PCOM requires that ovarian volume is caused by stromal expansion seen
in polycystic ovary syndrome (PCOS) and is not confounded by the volume of a
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dominant follicle. Thus to make full use of this volume cutoff, those that had
enlarged ovaries but also some “volume confounder”2 that contributed to this
increased volume had to be noted and marked as “unidentifiable in the current
examination,” as per the 2006 AE-PCOS task force guideline, “Evidence of a dom-
inant follicle or a corpus luteum necessitates examination during the next cycle
and presence of an abnormal cyst or ovarian asymmetry further investigation”
[15]. Thus, following the criteria guidelines, an ultrasound classifier should sort
pelvic ultrasouds into PCOM-present, PCOM-absent, and unidentifiable.3
If ovaries were larger than the cutoff and there were no volume confounders,
they were considered to have PCOM. If volume confounders were present, then
they were marked as unidentifiable. If the ovaries were smaller than the cutoff,
then they were marked as free from PCOM.
Many ultrasounds also included sentences with language similar to the fol-
lowing: numerous follicles arranged in a peripheral distribution indicative of
PCOS, and although fewer also explicitly gave counts for the amount of follicles,
those that included both found greater than 10 follicles. Therefore, ultrasounds
including phrases equivalent to numerous peripheral follicles also were recog-
nized as having PCOM.
Algorithm 1 summarizes the strategy and it is equivalent to the coding
schema outlined in Table 5.1:
2A more precise definition of this term will be given in section 5.2.4
3“Unidentifiable” is an actual category and is not the same as missing data, as this is what a
trained human ultrasonographer should declare the ovaries to be with regards to PCOM status.
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Algorithm 1 Ultrasound classifier pseudocode
1: procedure Calculate ovarian volumes
2: for all ovaries do
3: extract ovarian measurements with regular expressions
4: procedure Determine presence of volume confounders
5: . details given in section 5.2.4
6: procedure Determine presence of numerous peripheral follicles
7: . details given in section 5.2.4
8: procedure Classifying each ovary
9: for all ovaries do
10: if this ovary has “numerous peripheral follicles” then
11: mark it as PCOM-present
12: else if this ovary is larger than 10 ml then
13: check for the presence of a volume confounder.
14: if a ”volume confounder” is present in this ovary then
15: mark the ovary as “undiscernible in this ultrasound”
16: else
17: mark the ovary as PCOM-present
18: else if this ovary is smaller than 10 ml then
19: mark the ovary as PCOM-absent
20: else if this ovary is not visualized then
21: mark the ovary as “undiscernible in this ultrasound”
22: procedure Classifying patient status
23: for all patients do
24: if either ovary is PCOM-present then
25: the subject has PCOM
26: else if both ovaries are PCOM-absent then
27: the subject does not have PCOM
28: else if one ovary is PCOM-absent and the other is undiscernible then
29: the subject does not have PCOM
30: else if both ovaries are undiscernible then
31: the subject is undiscernible in this evaluation
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5.2.3 Evaluation of ovarian volumes
The ovarian measurements were fairly regular. Most tended to be in the form
“#.# × #.# × #.#cm” and variations tended to occur in spacing, use of centimeters
vs millimeters, and the number of significant digits. Units were converted and
variation in spacing and number of digits was taken care of by using regular ex-
pressions in the stringr package in R by Hadley Wickham [153]. The one used
here was:
[[:digit:]]+[.]∗[[:digit:]]∗[x][[:digit:]]+[.]∗[[:digit:]]∗[x][[:digit:]]+[.]∗[[:digit:]]∗. (5.1)
Another pitfall was that sometimes ultrasounds included 3 dimensional mea-
surements of other organs, such as kidneys and the uterus. In this case, sentences
mentioning these other organs were removed from each observation before ex-
tracting measurements. To calculate the volume, the formula
length × width × height × pi/6 (5.2)
as recommended in Balen et al. (2003) [19] is used.
5.2.4 Determining presence of volume confounders and numerous peripheral
follicles
In order to accurately distinguish between enlarged ovaries due to increased stro-
mal volume and enlarged ovaries due to recruitment of a dominant follicle or due
to presence of abnormal pathology, a comprehensive list of reasons that could con-
found the representation of stromal volume through total ovarian volume needed
to be determined.
This list was constructed empirically with natural language processing tech-
niques, by using the ultrasound text. The general idea is to find words and n-
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grams (phrases) correlated with a large ovarian volume, calculated previously.
This approach offered two distinct advantages: firstly, this ensured that all possi-
ble reasons in the dataset are accounted for once the full list of reasons is gener-
ated and secondly, this implicitly accounts for the natural language of the data, or
the multitude of ways radiologists could write about these volume confounders.
Typically these two problems are impossible to solve a priori. To do accomplish
this goal, two R packages were relied on extensively: the tm package by Ingo
Feinerer was used as a text mining framework and the SnowballC package by Mi-
lan Bouchet-Valat was used for its text stemming capabilities [21, 50, 51].
The first step was to create a Corpus, an abstract representation of the collec-
tion of documents, in this case, the collection of ultrasound notes. Each unique
ultrasound then becomes a document in this Corpus object. The next step was
cleaning the documents in theCorpus so that the natural language processing tools
from tm package could be applied. First, extra whitespace was stripped from each
document and punctuation removed. Since the actual way the word is expressed
is not as important as identifying similar concepts together, this allows “play”
and “play,” to be considered the same term. Next, all letters were converted to
lower case (R is case-sensitive), then numbers and English stopwords (a, the, for,
etc.) were removed, since they are not as informative and increase dimensionality
greatly. Here is how a typical document appears after this process:4
id
clinical date
history yearold female right lower quadrant cystic lesion identified ct scan april
patient dictaphone tb april
findings transvaginal pelvic ultrasound performed optimum visualization uterus
4Bolding and linebreaks are added for emphasis and legibility.
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adnexa transabdominal pelvic ultrasound performed evaluation remainder pelvic
contents uterus measures xx cm endometrial stripe measures mm myometrium
appears heterogeneous areas shadowing subtle cystic areas within myometrium
the appearance suggests adenomyosis no discrete submucosal fibroid identified
right ovary measures xx cm there cyst measuring approximately cm size located
centrally within right ovary thin rim peripheral tissue cyst hemorrhagic lowlevel
internal echoes no solid component mural nodule the cyst avascular taking ac-
count differences imaging technique cyst appears increased size compared ct scan
would recommend followup ultrasound approximately menstrual cycles if cyst
persists recommend mri evaluation left ovary measures xx left ovary normal no
free pelvic fluid limited evaluation right left kidneys demonstrates obstruction
impression approximate cm hemorrhagic appearing cyst right ovary appears en-
larged compared prior ct scan described would recommend followup ultrasound
approximate menstrual cycles if cyst persists recommend mri evaluation evidence
adenomyosis uterus mri can used confirm suspected adenomyosis clinically indi-
cated
After this point, the text is still relatively comprehensible. The final step of
preprocessing was a process called “stemming.” Stemming represents all words
with the same root as the same entity. For example “measures” and “measuring”
both become considered the same term, “measur.” After stemming, the text begins
to look more like a sequence of words. Here is how a typical ultrasound looks after
this process:
id
clinic date
histori yearold femal right lower quadrant cystic lesion identifi ct scan april pa-
tient dictaphon tb april
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find transvagin pelvic ultrasound perform optimum visual uterus adnexa trans-
abdomin pelvic ultrasound perform evalu remaind pelvic content uterus measur
xx cm endometri stripe measur mm myometrium appear heterogen area shadow
subtl cystic area within myometrium the appear suggest adenomyosi no discret
submucos fibroid identifi right ovari measur xx cm there cyst measur approxim
cm size locat central within right ovari thin rim peripher tissu cyst hemorrhag
lowlevel intern echo no solid compon mural nodul the cyst avascular take ac-
count differ imag techniqu cyst appear increas size compar ct scan would recom-
mend followup ultrasound approxim menstrual cycl if cyst persist recommend
mri evalu left ovari measur xx left ovari normal no free pelvic fluid limit evalu
right left kidney demonstr obstruct
impress approxim cm hemorrhag appear cyst right ovari appear enlarg compar
prior ct scan describ would recommend followup ultrasound approxim menstrual
cycl if cyst persist recommend mri evalu evid adenomyosi uterus mri can use con-
firm suspect adenomyosi clinic indic
After preprocessing, a document term matrix was constructed from the Cor-
pus. In a document term matrix (or term document matrix), each row represents
a document and each column represents a term. The number of rows corresponds
to the number of documents in the Corpus, and the number of rows corresponds to
the number of unique words in the entire Corpus (after stemming and exclusion
of stopwords). The document term matrix thus represents a table of frequency
counts with cells corresponding to the number of times each word appears in
each document (Table 5.2.4).
Since the goal is to find terms that represent structures that confound the
identification of large stromal volume, the next step was to use the ovarian vol-
umes calculated in Section 5.2.3 and crudely classify the ultrasound documents
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Table 5.2 Example document term matrix with m documents and n unique terms
Term 1 Term 2 Term 3 . . . Term n
Document 1 3 1 4 . . . 1
Document 2 5 9 2 . . . 6
Document 3 5 3 5 . . . 8
. . . . . . . . . . . . . . . . . .
Document m 9 7 9 . . . 3
Note. — For 0 ≤ i ≤ m and 0 ≤ j ≤ n, the {i,j} cell indicates frequency count for the number of
times term j appears in document i.
into those with large (>10 ml) and small (<10ml) ovaries. Next, the terms were
sorted into the order of their correlation with being either associated with either
large or small ovaries. Lastly, the top terms that represented a condition or struc-
ture that confounds the stromal volume were chosen manually [15]. Table 5.3
gives the list of volume confounders that were included as features after variable
selection. The ultrasounds reports that included these terms within the context of
describing the ovaries were marked as having volume confounders.
The process for identifying phrases that indicated the physician positively
identified PCOM was similar. Ultrasound reports that described ovaries as hav-
ing “numerous” or “peripheral” follicles or a “PCOS-like distribution” of follicles
indicated PCOM.
5.3 Results
Of the 39,093 observations, there were 8,439 observations classified as having
PCOM, 18,606 observations classified as not having PCOM, and 12,048 observa-
tions as unidentifiable. Among the 8439 observations of polycystic ovarian mor-
phology, there were 7104 unique patients.
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Table 5.3. Terms representing presence of volume confounders
Term Indicates presence of
Anechoic a region that is solid or fluid-filled
Corpus luteum a single dominant follicle
Cyst (singular) a single dominant follicle
Decreased
a structure noted on a previous
examination that is still present
Dermoid
an ovarian cyst containing hair,
bone, fluid, skin, or teeth
Dominant a single dominant follicle
Endometrioma
a cystic mass, formed from
endometrial tissue in the ovary
containing brown, tar-like fluid [103]
Follicle (singular) a single dominant follicle
Hemorrhagic
a cyst formed from bleeding into a
follicular or corpus luteal cyst [163]
Heterogeneity abnormal tissue within the ovary
Hypoechoic region a region that is solid or fluid-filled
Interval resolution
a structure noted on a previous
examination that is still present
Large an internal structure
Lesion an internal structure
Nodule an internal structure
Simple dominant follicles
Single an internal structure
Structure an internal structure
Two multiple internal structures
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5.4 Validation of methods
At the test time, a random sample of 1000 out of 39,093 were hand-checked for
accuracy. This was done blinded to the results of the automatic classification pro-
gram. The results are summarized in Table 5.4. Out of 1000 test cases, only 16
were incorrectly classified. Thus, the classification accuracy was 98.4%. Of these
16, further examination of examined why the model classified PCOM status incor-
rectly found that 7 errors were typographical errors very difficult for a program
to parse and 9 were errors due to the classifier.
Of the 7 typographical errors, 6 cases were due to a typo by the radiologist
in recording the measurements of ovaries; in one instance, the lack of a decimal
point (2.7x25x2.7 cm vs 2.7x2.5x2.7 cm) led to an absurdly high value. In another
case, a multiplication sign instead of a decimal point also led to a large value
(2x9x2.3x1.9 cm vs 2.9x2.3x1.9 cm). Sometimes errors appeared due to dicta-
tion software (2.7x2.6 six3.7 vs 2.7x2.6x3.7 cm) led to the string of text not being
recognized as a valid measurement text. The other case, “the left ovary” was in-
correctly written as “the left kidney” in a context that would be relatively easy
for a human with domain knowledge to recognize the mistake, but the program
reads the sentences too literally: “The right ovary measures 3.5x2.3x3.2cm and
the left kidney measures 2.6x3.2x3.3cm. Both ovaries are normal in size; shape
and echogenicity.” A human trained would be able to recognize these errors and
correct them, so these were still counted as errors of automatic classification.
The other 9 errors are attributed to the shortcomings classification method
itself, and they are all errors of not being able to incorporate relevant information
in a second sentence with a pronoun. For example, these sentences about the right
ovary were not understood to indicate that there is a volume confounder present:
“The right ovary is normal in size and echotexture and measures 2.5x3x2.3 cm.
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Table 5.4. Summary of error rates
Variable Error rate
Overall PCOM status 1.6% (16/1000)
Ovarian measurements 0.8% (16/2000)
Presence of numerous peripheral cysts 0.0% (0/2000)
Presence of volume confounder 1.2% (23/2000)
It contains a simple cyst measuring 2.4x2.1 cm.” More powerful natural language
processing methods such as object identification and part of speech tagging could
deal with the issues arising from information contained in second sentences with
pronouns. The program does not identify the “It” in the second sentence as the
same object as the right ovary mentioned in the first sentence. Still, an overall
error rate of 1.6% achieved with only shallow statistical learning methods is quite
impressive.
In addition to the overall PCOM status, each test case is associated with six
other variables: the ovarian volume, presence of numerous peripheral follicles in
the ovary and presence of a volume confounder in the ovary, on each side. Thus,
the program evaluates 6 ·1000 = 6000 other variables, and there were 40 variables
marked incorrectly. Here, the accuracy was 99.33%. Only 38 test cases contained
any errors, including the 16 whose overall PCOM status was classified incorrectly.
Thus, 22 others contained minor errors in secondary variables, but these did not
affect their overall classification. Notably, the error rate for identifying numerous
follicles in a peripheral orientation was perfect. Here, the reasons for the errors
were similar. Table 5.3 summarizes the errors.
Here is the multi-class confusion matrix 5.5 and the recall and precision for
the labels 5.6.
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Table 5.5 Multi-class confusion matrix for actual (A) vs predicted (P) ultrasound
classification labels
Absent (A) Unidentifiable (A) Present (A)
Absent (P) 474 1 0 475
Unidentifiable (P) 1 316 2 319
Present (P) 2 10 194 206
477 327 196 Totals
Table 5.6. Recall and precision for classification labels
Label Recall Precision
Absent 99.4% (474/477) 99.8% (474/475)
Unidentifiable 96.6% (316/327) 99.1% (316/319)
Present 99.0% (194/196) 94.2% (194/206)
5.5 Limitations
It is not guaranteed that this method would work well on similar ultrasound re-
port datasets generated throughout the Anglosphere. The major limitations of
this protocol are its indifference to pronouns and recognition of past vs. present.
Thus, a team of radiologists whose writing styles use these elements of language
more often than average would generate a more stubborn dataset.
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Chapter 6
Evaluation of PCOS in the study
6.1 Identifying PCOS
As mentioned in Section 2.1, the inclusion criteria of the study was record of at
least one aspect of the Rotterdam diagnostic criteria. Table 6.1 summarizes the
definition of the phenotypes ascertained in this study and Table 6.2 summarizes
the frequency counts for each of the phenotypes. In total, 2421 women were
identified as having polycystic ovary syndrome (PCOS). Of the Rotterdam phe-
notypes, the Non-PCO phenotype was the most commonly identified. Its fre-
quency relative to the other phenotypes should not be understood as representing
the proportion within the general population population, since far more women
(25,535) were evaluated for a pelvic ultrasound than testosterone lab (5254). In
order to draw population level estimates, poststratification would be first be nec-
essary [68].
6.2 Race-specific PCOS and undiagnosed PCOS
A recent study investigating PCOS prevalence have suggested that as many as
60% of PCOS cases may be undiagnosed [104]. The same study found that in their
sample, 30-50% of PCOS women were previously determined as being PCOS-free.
There exists an ICD-9 code for PCOS diagnoses 256.4 and throughout the
analysis, some patients were identified as having PCOS (by means of their lab,
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Table 6.1. Phenotype definitions
Phenotype HA IM PCOM
Frank PCOS + + +
Non-PCO PCOS + + -
Ovulatory PCOS + - +
Normoandrogenic PCOS - + +
Underdetermined PCOS1
1990 NIH PCOS + + Any
Andro-agnostic PCOS Any + +
Single cardinal feature
Only HA + - -
Only IM - + -
Only PCOM - - +
1The Any in the underdetermined subtypes
can take on all values. E.g. the Frank PCOS and
Non-PCO PCOS phenotypes are subsets of the
1990 NIH PCOS.
ultrasound, and menstrual data), but never having an ICD diagnosis. It is un-
clear how many of these actually represent undiagnosed cases – perhaps some
physicians will take note of the patients PCOS in other ways and not through the
ICD-9 code. In practice, a relatively extensive workup is required for a diagnosis
of PCOS, and a positive determination will usually be recorded with an ICD-9
code. Thus, it can said with fair certainty that those without ICD-9 codes are not
diagnosed with PCOS. Overall, 2421 patients were identified as having PCOS, and
of those, 1010 did not have an ICD-9 code indicating the presence of PCOS. An
apt question is then, what does this group of undiagnosed PCOS women “look”
like? In other words, what is the composition of this group?
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Table 6.2. Phenotype frequency
Phenotype Frequency
Study population 37959
All identifiable PCOS 2421
ICD identified PCOS 1411
No ICD PCOS 1010
Rotterdam phenotypes
Frank PCOS 124
Non-PCO PCOS 57
Ovulatory PCOS 140
Normoandrogenic PCOS 250
Underdetermined PCOS
1990 NIH PCOS 482
Andro-agnostic PCOS 876
Single cardinal feature
Only HA 111
Only IM 238
Only PCOM 310
Using a logistic regression model, odds ratio were calculated with race as a
predictor. Then compared to the White PCOS women, Black PCOS women have
2.09 times the odds of being undiagnosed. There also seems to be some moderate
disparity between non-Hispanic Whites and Hispanic patients, with the logistic
regression giving an odds ratio of 1.19. Given that a diagnosis of These results
are concerning especially in the light of evidence that shows that Hispanics and
Blacks are at greater risk for diabetes and cardiovascular disease [105, 119].
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Table 6.4. Odds of being undiagnosed
Race1 OR (95% CI)
Asian 1.00 (0.60, 1.63)
Black/African-American 2.09 (1.69, 2.59)
Hispanic/Latino 1.19 (0.90, 1.57)
Other/Multiracial 1.11 (0.72, 1.70)
1The referent group is Non-Hispanic White
women.
6.3 Conclusion
This thesis endeavored to lay the groundwork for a PCOS study based off the
Boston Medical Center (BMC) Clinical Data Warehouse (CDW) data. Chapter 1
gave an introduction to PCOS, Chapter 2 described the general characteristics
about the study population and aspects of cleaning the data, and Chapters 3, 4,
and 5 described the cardinal features of PCOS in this dataset.
Examination of error sources suggest there may be diminished returns in pur-
suing performance gains through more computationally intensive techniques like
word vectors and part of speech tagging. Future research in PCOS ultrasound
feature extraction should be directed towards methods for the raw ultrasound
images themselves. Ascertaining PCOS through the medical record offers advan-
tages over self-reported PCOS, including confirmation of disease and existence
of recorded measurements. This preliminary evidence indicates that Black PCOS
women may be at a greater risk of being undiagnosed. In the future, this work
could be used in conjunction with data on patients’ cardiovascular and metabolic
outcomes for studying the longitudinal health risks of PCOS.
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